Treatment of advanced hepatocellular carcinoma with HBsAg-targeted TCR engineered -T Cells: a case report

Abstract

Objective

To present the clinical course and outcome of a patient with advanced hepatocellular carcinoma (HCC) who received HBsAg-targeted T cell receptor-engineered T cells (TCR-T).

Case presentation

A 61-year-old man with advanced HCC developed cytokine release syndrome (CRS) after HBsAg-targeted TCR-T infusion, which met grade 3 criteria within 24 h and then rapidly improved to grade 2, alleviated after two weeks. Although hematologic toxicities were prominent, recovery was achieved and there were no severe consequences. At 6 weeks post-infusion, the patient's cervical lymph nodes and pulmonary metastases showed slight reduction, suggesting a possible transient therapeutic effect. However, by day 87 post-infusion, all lesions had progressed again. Meanwhile, the bone metastases demonstrated continuous progression.

Conclusion

HBsAg-targeted TCR-T cell therapy may represent a potential therapeutic strategy for advanced HCC, demonstrating a manageable safety profile when carefully monitored for ≥ Grade 3 cytokine release syndrome and hematological toxicities.

Keywords

Advanced hepatocellular carcinoma / TCR engineered-T cells / Hepatitis B surface antigen / Clinical course / Prognosis

References

[1] Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2023;21(1):47–66.

[2] BauluE, GardetC, ChuvinN, DepilS. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv, 2023, 97. eadf3700

[3] BrownZJ, TsilimigrasDI, RuffSM, MohseniA, KamelIR, CloydJM, PawlikTM. Management of hepatocellular carcinoma: a review. JAMA Surg, 2023, 158(4): 410-420.

[4] DrueyKM, ArnaudL, ParikhSM. Systemic capillary leak syndrome. Nat Rev Dis Primers, 2024, 10186.

[5] GalliE, SoràF, HohausS, FresaA, PansiniI, AutoreF, et al.. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. Br J Haematol, 2023, 201(1): 86-94.

[6] GuerraE, Di PietroR, BasileM, TrerotolaM, AlbertiS. Cancer-homing CAR-T cells and endogenous immune population dynamics. Int J Mol Sci, 2021.

[7] JiangH, LiuL, GuoT, WuY, AiL, DengJ, DongJ, MeiH, HuY. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol, 2019, 98(7): 1721-1732.

[8] RejeskiK, JainMD, ShahNN, PeralesMA, SubkleweM. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol, 2024, 11(6): e459-e470.

[9] Wang LX, Yu XQ, Cao J, Lu YL, Luo M, Lei F, et al. Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient. Int J Hematol. 2021;114(3):408–12.

RIGHTS & PERMISSIONS

The Author(s)